Back
46
22
Day Range
$19.00
$21.00
52-Week Range
$18.57
$35.00
Volume
760
50D / 200D Avg
$20.95
/
$25.69
Prev Close
$21.00
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 9.8 | 0.4 |
| P/B | 1.6 | 2.9 |
| ROE % | 17.8 | 3.8 |
| Net Margin % | 12.1 | 3.9 |
| Rev Growth 5Y % | 53.2 | 10.0 |
| D/E | 0.0 | 0.2 |
Key Takeaways
Revenue grew 53.17% annually over 5 years — strong growth
ROE of 17.81% — decent returns on equity
Debt/Equity of 0.01 — conservative balance sheet
Generating 218.19M in free cash flow
P/E of 9.75 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 22.80%
Growth
Revenue Growth (5Y)
53.17%
Revenue (1Y)30.37%
Earnings (1Y)6.01%
FCF Growth (3Y)N/A
Quality
Return on Equity
17.81%
ROIC23.61%
Net Margin12.10%
Op. Margin23.55%
Safety
Debt / Equity
0.01
Current Ratio4.85
Interest Coverage8.60
Valuation
P/E Ratio
9.75
P/B Ratio1.60
EV/EBITDA3.69
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 30.37% | Revenue Growth (3Y) | 40.80% |
| Earnings Growth (1Y) | 6.01% | Earnings Growth (3Y) | -23.93% |
| Revenue Growth (5Y) | 53.17% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.17B | Net Income (TTM) | 141.80M |
| ROE | 17.81% | ROA | 13.72% |
| Gross Margin | 92.57% | Operating Margin | 23.55% |
| Net Margin | 12.10% | Free Cash Flow (TTM) | 218.19M |
| ROIC | 23.61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 4.85 |
| Interest Coverage | 8.60 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 9.75 | P/B Ratio | 1.60 |
| P/S Ratio | 1.18 | PEG Ratio | 21.62 |
| EV/EBITDA | 3.69 | Dividend Yield | 0.00% |
| Market Cap | 1.38B | Enterprise Value | 1.02B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 898.73M | 591.08M | 328.82M | 212.89M |
| Net Income | 141.80M | 133.75M | 245.02M | -68.17M | -85.53M |
| EPS (Diluted) | 2.12 | 2.01 | 3.74 | -1.06 | -1.34 |
| Gross Profit | 1.08B | 832.25M | 540.92M | 297.71M | 189.70M |
| Operating Income | 275.98M | 166.15M | 13.93M | -64.54M | -80.67M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.03B | 879.69M | 688.82M | 371.82M | 343.92M |
| Total Liabilities | 168.46M | 152.23M | 143.64M | 102.89M | 78.22M |
| Shareholders' Equity | 865.08M | 727.46M | 545.18M | 268.93M | 265.70M |
| Total Debt | 11.68M | 14.59M | 17.48M | 17.45M | 21.42M |
| Cash & Equivalents | 377.04M | 227.00M | 166.93M | 201.28M | 206.46M |
| Current Assets | 794.66M | 622.60M | 402.94M | 338.81M | 308.48M |
| Current Liabilities | 163.91M | 144.19M | 130.06M | 90.20M | 61.70M |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#477 of 1024
#391 of 658
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026